Status:
UNKNOWN
A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
Lead Sponsor:
Hebei Medical University Fourth Hospital
Conditions:
Stage III Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for breast cancer pa...
Eligibility Criteria
Inclusion
- Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis)
- Age 18-70
- No evidence of distant metastasis
- No previous therapy
- Normal hematologic function
- No abnormality of renal or liver function
- Written informed consent
Exclusion
- With allergic constitution or possible allergic reflection to drugs to be used in this study
- Any concurrent uncontrolled medical or psychiatric disorder
- History of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease
- Being pregnant or nursing
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01907529
Start Date
August 1 2019
End Date
December 1 2021
Last Update
August 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, China
Shijiazhuang, Hebei, China, 050011